Navigation Links
The molecular mechanism of a diabetes vaccine revealed

A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of ScienceImmunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials. Type 1 diabetes is an autoimmune disorder in which the immune system mistakenly attacks the body's own insulin-producing pancreatic cells, reducing and ultimately eliminating the production of insulin ?a hormone needed to convert sugar, starches, and other foods into energy.

Several years ago, Prof. Cohen and colleagues developed a vaccine that arrests the progression of Type 1 diabetes in laboratory animals. They had discovered that a particular protein called HSP60, or even only a small particular fragment of it ?the peptide designated p277 ?is able to shut down the autoimmune response causing this disorder. The vaccine is currently being tested in clinical trials in Europe and the United States, but its precise mechanism has until now been unknown.

"When translating these findings into a practical vaccine, we knew enough about the mechanism to understand that this protein is able to cause a decrease in the immune response, but how it actually works eluded us," says Cohen. In a paper published in the Journal of Clinical Investigation, the scientists have managed to identify the exact immune cells that p277 acts upon and its mechanism of action.

Autoimmune diseases occur when certain T cells in the immune system attack the body's own cells and tissues. The scientists discovered that p277 directs the activity of the immune system in two ways. First, the p277 peptide steps up the activities of a different type of T cell that regulates the amount of potentially harmful T cells available. In addition, T cells treated with p277 cause the delinquent T cells to secrete anti-inflammatory substances instead of the inflammation-causing ones that they u sually make which lead to autoimmune disease. This double action of the peptide weakens the damaging activities of the immune response further. The scientists also showed that in order to activate this response, p277 must be bound to the receptor TLR-2, which is found on the cell walls of the regulatory T cells.

"These findings are important, as it means that by identifying the molecular activity of p277 with such precision, we can copy nature's own system in regulating the immune system and therefore, help to boost the immune system in preventing the destruction of insulin-producing pancreatic cells," says Cohen.

Postdoctoral fellow Dr. Alexandra Zanin-Zhorov spearheaded the project; the other scientists participating in this study were: the late Prof. Ofer Lider, Dr. LioraCahalon, postdoctoral fellow Guy Tal, and Raanan Margalit.


'"/>

Source:American Committee for the Weizmann Institute of Science


Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Source of molecular triggers in cutaneous T cell lymphoma identified
3. Plants, animals share molecular growth mechanisms
4. NYU researchers simulate molecular biological clock
5. Scientists reveal molecular secrets of the malaria parasite
6. Scientists identify molecular events that drive cell senescence
7. Researchers discover molecular mechanism that desensitizes us to cold
8. Findings have implications for tracking disease, drugs at the molecular level
9. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
10. At the molecular level, the predator is the prey
11. By creating molecular bridge, scientists change function of a protein
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: